SCHEMBL23547713

SCHEMBL23547713

COC1C(CO)OC(n2cnc3c(N)ncnc32)C1F

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 4/20 0.64
PI4KA P42356 2/20 0.64
PI4K2B Q8TCG2 2/20 0.64
PI4K2A Q9BTU6 2/20 0.64
PI4KB Q9UBF8 2/20 0.64
ADORA1 P30542 2/20 0.64
DPP4 P27487 1/20 0.64
MEN1 O00255 1/20 0.64
SLC28A1 O00337 1/20 0.64
MAP3K7 O43318 1/20 0.64
SLC28A2 O43868 1/20 0.64
GAPDH P04406 1/20 0.64
MAPK1 P28482 1/20 0.64
ADORA2A P29274 1/20 0.64
ADORA2B P29275 1/20 0.64
STAT6 P42226 1/20 0.64
KMT2A Q03164 1/20 0.64
SMN1; SMN2 Q16637 1/20 0.64
DOT1L Q8TEK3 1/20 0.64
SLC29A1 Q99808 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22855773 1.00 ADORA3 (0.64) ADORA3PI4KAPI4K2BPI4K2API4KB
SCHEMBL20870832 0.90 ADORA3 (0.67) ADORA3PI4KAPI4K2BPI4K2API4KB
SCHEMBL8621803 0.90 ADORA3 (0.67) ADORA3PI4KAPI4K2BPI4K2API4KB
SCHEMBL8672670 0.90 ADORA3 (0.67) ADORA3PI4KAPI4K2BPI4K2API4KB
SCHEMBL22855523 0.89 NT5E (0.54) ADORA3PI4KAPI4K2BPI4K2API4KB
SCHEMBL24371508 0.89 ADORA3 (0.64) ADORA3PI4KAPI4K2BPI4K2API4KB
SCHEMBL21999052 0.88 ADORA3 (0.76) ADORA3PI4KAPI4K2BPI4K2API4KB
SCHEMBL23547979 0.88 ADORA3 (0.75) ADORA3PI4KAPI4K2BPI4K2API4KB
SCHEMBL16359953 0.88 ADORA3 (0.75) ADORA3PI4KAPI4K2BPI4K2API4KB
SCHEMBL21418864 0.88 ADORA3 (0.75) ADORA3PI4KAPI4K2BPI4K2API4KB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220125825-A1 S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS ALIGOS THERAPEUTICS, INC. 2022-04-28 US disclosed
US-20210189392-A1 S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS ALIGOS THERAPEUTICS, INC. 2021-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220125825-A1 S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS RNGTT, PHAX, HAVCR2 ADORA3 1372/4885PI4KA 3950/4885PI4K2B 4093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.